Direct oral anticoagulants versus vitamin K antagonists in patients with atrial fibrillation and stage 5 chronic kidney disease under dialysis: A systematic review and meta-analysis of randomized controlled trials

[1] Virani SS(2021)Heart disease and stroke statistics – 2021 update: a report from the American Heart Association Circulation 143 e254-e743

[2] Alonso A(2011)The increasing prevalence of atrial fibrillation among hemodialysis patients J Am Soc Nephrol 22 349-357

[3] Aparicio HJ(2019)Atrial fibrillation in patients with end-stage renal disease on hemodialysis: magnitude of the problem and new approach to oral anticoagulation Res Pract Thromb Haemost 3 578-588

[4] Winkelmayer WC(2015)Risk factors of ischemic stroke and subsequent outcome in patients receiving hemodialysis Stroke 46 2477-2481

[5] Patrick AR(2019)2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines and the heart rhythm society in collaboration with the Society of thoracic surgeons Circulation 140 e125-e151

[6] Liu J(2017)Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis Am Heart J 184 37-46

[7] Brookhart MA(2019)Anticoagulation in concomitant chronic kidney Disease and Atrial Fibrillation: JACC Review topic of the Week J Am Coll Cardiol 74 2204-2215

[8] Setoguchi S(2022)Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis Future Cardiol 18 393-405

[9] Königsbrügge O(2022)Direct oral anticoagulants in patients on chronic Dialysis and concomitant Atrial Fibrillation: a Common Clinical Impasse Front Biosci (Schol Ed) 14 21-1483

[10] Ay C(2021)Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis patients with Atrial Fibrillation: a Multicenter Randomized Controlled Trial J Am Soc Nephrol 32 1474-1745

[1] Virani SS(2021)Heart disease and stroke statistics – 2021 update: a report from the American Heart Association Circulation 143 e254-e743

[2] Alonso A(2011)The increasing prevalence of atrial fibrillation among hemodialysis patients J Am Soc Nephrol 22 349-357

[3] Aparicio HJ(2019)Atrial fibrillation in patients with end-stage renal disease on hemodialysis: magnitude of the problem and new approach to oral anticoagulation Res Pract Thromb Haemost 3 578-588

[4] Winkelmayer WC(2015)Risk factors of ischemic stroke and subsequent outcome in patients receiving hemodialysis Stroke 46 2477-2481

[5] Patrick AR(2019)2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS Guideline for the management of patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice guidelines and the heart rhythm society in collaboration with the Society of thoracic surgeons Circulation 140 e125-e151

[6] Liu J(2017)Vitamin K antagonists for stroke prevention in hemodialysis patients with atrial fibrillation: a systematic review and meta-analysis Am Heart J 184 37-46

[7] Brookhart MA(2019)Anticoagulation in concomitant chronic kidney Disease and Atrial Fibrillation: JACC Review topic of the Week J Am Coll Cardiol 74 2204-2215

[8] Setoguchi S(2022)Real-world evidence comparing oral anticoagulants in non-valvular atrial fibrillation: a systematic review and network meta-analysis Future Cardiol 18 393-405

[9] Königsbrügge O(2022)Direct oral anticoagulants in patients on chronic Dialysis and concomitant Atrial Fibrillation: a Common Clinical Impasse Front Biosci (Schol Ed) 14 21-1483

[10] Ay C(2021)Safety and Efficacy of Vitamin K Antagonists versus Rivaroxaban in Hemodialysis patients with Atrial Fibrillation: a Multicenter Randomized Controlled Trial J Am Soc Nephrol 32 1474-1745